Expected Moves

Given Akari’s shrinking cash balance and elevated burn, the market is braced for an equity financing or alternative capital raise around late 2026, with a constructive outcome taking the stock toward $6.00 if terms are manageable, or toward $6.00 if the raise is deep-discounted or highly dilutive.

Expected update on Nomacopan development strategy in HSCT-TMA, including regulatory feedback and trial design clarity, which could re-rate Akari sharply higher toward $16.00 if it confirms a viable registrational path, or lower toward $16.00 if timelines slip or the path is unclear.

A year-end 2026 pipeline and strategic update, likely via investor presentation or press releases, could support a recovery toward $2.40 if Akari demonstrates tangible progress on Nomacopan and outlines credible partnering paths, or lead to further erosion toward $2.40 if timelines slip and no external validation emerges.

Q3 2026 results will frame post-financing burn, updated cash runway, and any Nomacopan timeline shifts, with potential recovery toward $3.20 if expenses are controlled and runway is extended, or drift toward $3.20 if burn remains high and visibility is poor.

Q4 2026 earnings will recap a full year of burn and funding actions, with room for a recovery toward $1.00 if Akari shows it can stretch cash while advancing Nomacopan, or further downside toward $1.00 if the year closes with strained liquidity and limited clinical progress.